Search Results for: Clinical Trial

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Melanoma Literature
Publication date: Jan 02, 2020 Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. To investigate the association between irAEs and recurrence-free ... Read more